Randy King

Our laboratory studies how ubiquitin‐dependent protein degradation controls cell cycle progression in normal and cancer cells. We integrate biochemical, cell biological, and chemical approaches to study the ubiquitin-proteasome pathway. We are interested in the regulation of the Anaphase‐Promoting Complex (APC), a large multisubunit ubiquitin ligase that targets  important mitotic regulators for destruction by the ubiquitin pathway. We are especially interested in the development of new small molecule inhibitors that block APC-dependent degradation, which may be useful for treatment of cancer. Recently, we have also identified small molecules that accelerate proteasomal degradation, which may be useful for treatment of neurodegerative disease.  We are also interested in the development of new technologies including novel screening methods and imaging approaches, including long-term time lapse imaging.